Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
BMO projects peak sales of $2.4 billion for Cobenfy in schizophrenia and $3.9 billion in Alzheimer's related-psychosis, raising the price target to $53 from $48, with a Market Perform rating.On Thursday, the FDA approved Bristol Myers Squibb & Co's (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.
上周四，FDA批准了傲石明治（KarXT，karuna therapeutics）口服药物Cobenfy（艾左氨咪明和曲斯匹克氯化铜，用于成年精神分裂症治疗）
BMO Capital analyst notes that the FDA approval without a boxed warning is a significant positive for Bristol Myers shares.
BMO Capital 分析师指出，FDA批准未含装箱警告对Bristol Myers股价是一个重大利好。
The analyst notes that given that many prior antipsychotic medications received black box warnings due to increased mortality risks, particularly in elderly patients, Cobenfy's absence of such a warning could significantly enhance its potential in treating Alzheimer's related-psychosis, pending further clinical trials.
分析师指出，鉴于许多既往的抗精神病药物由于增加死亡风险而收到黑框警告，尤其是在老年患者中，Cobenfy缺乏这样的警告可能会显著增强其在治疗与阿尔兹海默病相关的精神病方面的潜力，待进一步临床试验。
BMO projects peak sales of $2.4 billion for Cobenfy in schizophrenia and $3.9 billion in Alzheimer's related-psychosis, raising the price target to $53 from $48, with a Market Perform rating.
BMO预测Cobenfy在精神分裂症的最高销售额为24亿美元，在与阿尔兹海默病相关的精神病的销售额则为39亿美元，将价格目标提高至53美元，从48美元，评级为市场表现。
The analyst notes that Cobenfy will be priced at $1,850 for a 30-day supply or $22,500/year, representing a discount to previous expectations.
分析师指出，Cobenfy的售价为1850美元，供应量为30天，或每年22500美元，相对于先前的预期折扣。
Truist Securities highlights that AbbVie Inc (NYSE:ABBV) is also advancing emraclidine as a treatment for schizophrenia and Alzheimer's disease-related psychosis.
Truist Securities强调AbbVie Inc（NYSE:ABBV）也正在推进emraclidine作为治疗精神分裂症和阿尔兹海默病相关精神病的药物。
According to Truist analysts, emraclidine differs from KarXT in its mechanism of action.
根据Truist分析师，emraclidine在其作用机制上与KarXt有所不同。
Despite emerging competition, Truist points out that KarXT holds a first-mover advantage and is ahead by at least two to three years.
尽管出现了竞争，Truist指出KarXt拥有先发优势，至少领先了两到三年。
Truist maintains the Buy rating and a price target of $62.
Truist维持买入评级，并将目标价设定为62美元。
William Blair projects peak U.S. sales for Cobenfy to reach approximately $2 billion by 2030, driven solely by its use in treating schizophrenia.
William Blair预计，到2030年，Cobenfy在美国的销售额将达到约200亿美元的峰值，这仅仅是由其在治疗精神分裂症方面的应用推动的。
However, if the drug is approved for additional indications, such as Alzheimer-related psychosis and adjunctive schizophrenia—both currently in Phase 3 trials—annual sales could rise to around $3 billion to $5 billion, pending positive results.
然而，如果这种药物获得额外适应症的批准，比如目前正在进行第三阶段试验的阿尔茨海默症相关精神病和附加精神分裂症，年销售额可能会增至约300亿至500亿美元，前提是获得积极的结果。
The analyst points out that although the label lacks a black box warning, it does include caution for urinary retention, elevated heart rate, reduced gastric motility, and angioedema.
分析师指出，尽管说明书中没有黑框警告，但却包含对尿潴留，心率升高，胃动力减低和血管水肿的警告。
Price Action: BMY stock is up 2.33% at $51.29 at the last check on Friday.
股价走势：BMY股票在上周五最后一次检查时上涨了2.33%，报收51.29美元。
- FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate.
- FDA取消对Biomea Fusion潜在糖尿病候选药物早期试验的临床暂停。
